Introducing the new Polycarp Research Platform ๐
Find the best setups in the market with live dashboards of risk and opportunities, seasonal paths and technicals, and that isn't even the warm up. ๐
The trial is totally free, let me know what you think and hope you enjoy, cheers ๐ฟ (direct link in the comments)
Per Citadel, yesterday was the 7th largest call-buying sessions on record among retail (and the largest in 2 years since January of 2025)
Meanwhile institutional options activity was overwhelmingly defensive, with clients monetizing and rolling downside hedges, noting little appetite to buy the dip
$COGT โ Nov. 30 PDUFA (GIST) and a second one Dec. 30 (non-advanced SM), with advanced SM on Jun. 29, 2027. PEAK doubled PFS where ripretinib couldn't beat sunitinib. Base $32, roughly the price; bull $82.
Biotech setups with upcoming catalyst can be a gift ๐ during overall market pullbacks $XBI
Here are a few ๐งต
$CYTK Nov. 14 FDA target date (MAPLE-HCM label update, monotherapy vs. metoprolol), Q3 on Nov. 4, nHCM sNDA filing in Q4. ACACIA worked where Bristol's ODYSSEY failed. Base $65 vs. a $105 Street average.
Maybe I should do a video specifically on trading bear trends. Most traders really struggle as it is NOT the same as flipping your chart upside down and treating it like an uptrend. If thereโs interest . . .
I havenโt done anything like that for the community so maybe Iโll do a non paywalled version and then a more in depth version for the membersโ starter kit or intro course๐ค